Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer

NCT01226407 is registered in ClinicalTrials.gov with CrystalGenomics, Inc. as lead sponsor.

NCT NCT01226407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01226407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer
Lead sponsor
CrystalGenomics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2010
Completion date
February 28, 2013
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumour